Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Coca-Cola Co N.COLA


Primary Symbol: KO

The Coca-Cola Company is a beverage company. The Company's segments include Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures and Bottling Investments. It owns or licenses and markets various beverage brands, which are grouped into categories, such as Trademark Coca-Cola; sparkling flavors; water, sports, coffee and tea; juice, value-added dairy and plant-based beverages and emerging beverages. It owns and markets various nonalcoholic sparkling soft drink brands, including Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero Sugar, Fanta, Fresca, Schweppes, Sprite and Thums Up. Its water, sports, coffee and tea brands include Aquarius, Ayataka, BODYARMOR, Ciel, Costa, Dasani, dogadan, FUZE TEA, Georgia, glaceau smartwater, glaceau vitaminwater, Gold Peak, Ice Dew, I LOHAS, Powerade and Topo Chico. Its juice, value-added dairy and plant-based beverages brands include AdeS, Del Valle, fairlife, innocent, Minute Maid, Minute Maid Pulpy and Simply.


NYSE:KO - Post by User

<< Previous
Bullboard Posts
Next >>
Post by Namiiion Jun 03, 2022 3:52am
236 Views
Post# 34728658

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance


FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.


 
<< Previous
Bullboard Posts
Next >>